CENTRAL TRUST Co Sells 239 Shares of STERIS plc (NYSE:STE)

CENTRAL TRUST Co decreased its position in STERIS plc (NYSE:STE) by 16.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,223 shares of the medical equipment provider’s stock after selling 239 shares during the quarter. CENTRAL TRUST Co’s holdings in STERIS were worth $297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of STE. Wealth Enhancement Advisory Services LLC grew its holdings in shares of STERIS by 14.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,140 shares of the medical equipment provider’s stock valued at $1,156,000 after purchasing an additional 663 shares in the last quarter. Congress Wealth Management LLC DE lifted its position in STERIS by 61.8% during the first quarter. Congress Wealth Management LLC DE now owns 115,916 shares of the medical equipment provider’s stock valued at $26,060,000 after purchasing an additional 44,288 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of STERIS by 4.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,436 shares of the medical equipment provider’s stock worth $2,796,000 after buying an additional 529 shares in the last quarter. Dash Acquisitions Inc. grew its stake in shares of STERIS by 5.2% in the 1st quarter. Dash Acquisitions Inc. now owns 22,278 shares of the medical equipment provider’s stock worth $5,009,000 after buying an additional 1,100 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of STERIS by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 237,155 shares of the medical equipment provider’s stock worth $53,317,000 after buying an additional 1,075 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Performance

STE stock opened at $224.12 on Friday. STERIS plc has a twelve month low of $195.47 and a twelve month high of $248.24. The firm has a market cap of $22.10 billion, a price-to-earnings ratio of 55.61 and a beta of 0.84. The business’s fifty day simple moving average is $234.76 and its two-hundred day simple moving average is $226.34. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35.

STERIS (NYSE:STE) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $1.98 by $0.16. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The firm’s revenue was down .4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.00 EPS. Analysts predict that STERIS plc will post 9.06 earnings per share for the current year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were issued a $0.57 dividend. This is a positive change from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.02%. STERIS’s payout ratio is presently 56.58%.

Insider Buying and Selling

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $230.00 to $260.00 in a report on Thursday. StockNews.com raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 21st. KeyCorp increased their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.